###begin article-title 0
###xml 102 110 99 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro
###end article-title 0
###begin title 1
Introduction
###end title 1
###begin p 2
###xml 495 501 <span type="species:ncbi:10090">murine</span>
###xml 517 522 <span type="species:ncbi:10090">mouse</span>
Transforming growth factor (TGF)-beta1 is proposed to inhibit the growth of epithelial cells in early tumorigenesis, and to promote tumor cell motility and invasion in the later stages of carcinogenesis through the induction of an epithelial to mesenchymal transition (EMT). EMT is a multistep process that is characterized by changes in cell morphology and dissociation of cell-cell contacts. Although there is growing interest in TGF-beta1-mediated EMT, the phenotype is limited to only a few murine cell lines and mouse models.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 362 363 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
###xml 140 145 <span type="species:ncbi:9606">human</span>
To identify alternative cell systems in which to study TGF-beta1-induced EMT, 18 human and mouse established cell lines and cultures of two human primary epithelial cell types were screened for TGF-beta1-induced EMT by analysis of cell morphology, and localization of zonula occludens-1, E-cadherin, and F-actin. Sensitivity to TGF-beta1 was also determined by [3H]thymidine incorporation, flow cytometry, phosphorylation of Smad2, and total levels of Smad2 and Smad3 in these cell lines and in six additional cancer cell lines.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
TGF-beta1 inhibited the growth of most nontransformed cells screened, but many of the cancer cell lines were insensitive to the growth inhibitory effects of TGF-beta1. In contrast, TGF-beta1 induced Smad2 phosphorylation in the majority of cell lines, including cell lines resistant to TGF-beta1-mediated cell cycle arrest. Of the cell lines screened only two underwent TGF-beta1-induced EMT.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
The results presented herein show that, although many cancer cell lines have lost sensitivity to the growth inhibitory effect of TGF-beta1, most show evidence of TGF-beta1 signal transduction, but only a few cell lines undergo TGF-beta1-mediated EMT.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 203 204 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 205 206 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Transforming growth factor (TGF)-beta1 is a cytokine that is involved in immune suppression, angiogenesis, apoptosis, cell growth, and epithelial to mesenchymal transitions (EMTs) during carcinogenesis [1-7]. TGF-beta1 signals through the TGF-beta type I (TbetaRI) and TGF-beta type II (TbetaRII) transmembrane serine/threonine protein kinase receptors.
###end p 10
###begin p 11
###xml 565 566 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 567 569 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
When TGF-beta1 binds TbetaRII, TbetaRI is recruited to TbetaRII, and TbetaRII phosphorylates and activates the kinase activity of TbetaRI. Activated TbetaRI interacts with and phosphorylates a number of proteins, thereby activating many downstream signaling pathways, including the Smad (Sma/Mothers Against Decapentaplegic) pathway. The Smad signaling cascade is initiated by the phosphorylation of Smad2 or Smad3 by TbetaRI. Phosphorylated Smad2 and Smad3 associate with Smad4 and are translocated to the nucleus, where they modulate transcription of many genes [8-13].
###end p 11
###begin p 12
###xml 163 164 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 165 166 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 323 325 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 326 328 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 443 445 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 446 448 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 464 466 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 485 487 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 488 490 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 507 509 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 510 512 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 534 536 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 555 557 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 558 560 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 601 603 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 604 606 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 789 794 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MADH2</italic>
###xml 807 812 789 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MADH4</italic>
###xml 878 880 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 895 897 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 916 918 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 919 921 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 169 184 <span type="species:ncbi:10090">Transgenic mice</span>
In early tumorigenesis TGF-beta1 inhibits the growth of epithelial cells, and insensitivity to this growth inhibitory effect is associated with tumor progression [5,6]. Transgenic mice expressing a dominant negative TbetaRII in the epidermis and mammary glands exhibit accelerated tumor formation and malignant conversion [14,15]. Resistance to the antiproliferative effects of TGF-beta1 is observed in head and neck squamous cell carcinomas [16-18], lung cancer [19], gastric cancer [20-22], colon cancer [22-25], pancreatic cancer [26], ovarian cancer [27,28], and in some recurrent breast cancers [29,30]. This loss of sensitivity to TGF-beta1 is due to mutations in or transcriptional repression of the genes that encode TbetaRI and/or TbetaRII. Mutations in the genes encoding Smad2 (MADH2) and Smad4 (MADH4) also contribute to the insensitivity to TGF-beta1 in many lung [31], pancreatic [32], and colorectal [33,34] carcinomas.
###end p 12
###begin p 13
###xml 210 211 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 212 213 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 276 278 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 290 292 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 302 304 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 315 317 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 318 320 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 348 350 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 640 642 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 918 920 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 921 923 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1087 1089 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1090 1092 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1093 1095 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1096 1098 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 665 670 <span type="species:ncbi:10090">mouse</span>
###xml 912 916 <span type="species:ncbi:10090">mice</span>
###xml 1081 1085 <span type="species:ncbi:10090">mice</span>
In contrast to the growth inhibitory effects of TGF-beta1 in the early stages of carcinogenesis, TGF-beta1 can also act as a promoter of tumor cell invasion and metastasis in the later stages of tumorigenesis [5,6]. Increased production of TGF-beta1 is observed in epidermal [35], gastric [36], renal [37], breast [38-41], and prostate carcinomas [42] when compared with normal tissues. In mice with polyomavirus middle T antigen expression targeted to the mammary gland, blockade of TGF-beta1 by administration of Fc:TbetaRII results in increased apoptosis in primary tumors and reduced tumor cell motility, intravasation, and metastasis [43]. Chronic exposure of mouse epidermal cells to TGF-beta1 results in loss of TGF-beta1-mediated growth inhibition and marked changes in cell morphology, downregulation of E-cadherin and cytokeratins, upregulation of vimentin, and formation of spindle cell carcinomas in mice [44,45]. Further studies show that carcinomas with excess TGF-beta1 production are more motile and invasive, and exhibit increased tumor cell metastasis in athymic mice [36,40,45-51].
###end p 13
###begin p 14
###xml 111 113 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 222 224 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 225 227 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 507 509 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 510 512 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 758 760 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 761 763 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
One mechanism by which TGF-beta1 can promote tumor cell motility and invasion is through the induction of EMT [52]. EMT is a complex process that involves changes in cell morphology and dissociation of cell-cell contacts [53,54]. Cells undergoing EMT change from a cobblestone-like appearance to an elongated, mesenchymal phenotype. Accompanying this morphologic change is the delocalization of adherens and tight junctional proteins from the cell-cell junctions, and remodeling of the actin cyto-skeleton [53,54]. Characteristics associated with EMT, such as the dissociation of cell-cell and cell-extracellular matrix contacts, acquisition of an elongated cell morphology, and rearrangement of the cytoskeleton, can facilitate cell migration and invasion [55-57].
###end p 14
###begin p 15
###xml 56 63 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 104 113 98 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 289 294 <span type="species:ncbi:10090">mouse</span>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 1427 1433 <span type="species:ncbi:10090">murine</span>
Although TGF-beta1 is thought to play a key role in EMT in vivo, the frequency of TGF-beta1-induced EMT in vitro is not known. To identify alternative cell systems in which to study TGF-beta1-mediated EMT, we screened primary cultures of two human epithelial cell types and 18 established mouse and human cell lines for TGF-beta1 responsiveness. We also included six additional cancer cell lines as a comparison for TGF-beta1 responsiveness. We found that many of the cell strains displayed morphological changes and exhibited actin stress fiber responses to TGF-beta1. However, only in the NMuMG and MCT cells were those changes accompanied by a loss of E-cadherin and zonula occludens (ZO)-1 at cell-cell junctions after 48 hours of TGF-beta1 treatment. Whereas all of the nontransformed cells were growth inhibited by TGF-beta1, many of the cancer cell lines were insensitive to the growth inhibitory effects of TGF-beta1. The TGF-beta1-mediated growth inhibition was accompanied by an increase in phosphorylated Smad2 protein levels, but this was not unique to growth inhibited cells because changes in Smad2 phosphorylation occurred in a majority of cells after TGF-beta1 treatment. In addition, prolonged TGF-beta1 treatment induced a decrease in total Smad2 and/or total Smad3 in some cell lines. Our findings show that, although many cancer cells lost sensitivity to the growth inhibitory effect of TGF-beta1, only two murine cell lines underwent TGF-beta1-mediated EMT and these cells retain growth inhibitory response to TGF-beta1.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Cell lines and culture conditions
###end title 17
###begin p 18
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 214 219 <span type="species:ncbi:9606">human</span>
###xml 256 261 <span type="species:ncbi:9606">human</span>
###xml 262 268 <span type="species:ncbi:9606">infant</span>
###xml 361 366 <span type="species:ncbi:9606">human</span>
###xml 500 505 <span type="species:ncbi:10090">Mouse</span>
###xml 679 684 <span type="species:ncbi:10090">mouse</span>
###xml 764 792 <span type="species:ncbi:11808">Kirsten murine sarcoma virus</span>
A549, BT549, DU145, H1299, HBL100, MCF10A, MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-435S, MDA-MB-436, MDA-MB-468, NMuMG, and 4T1 cells were purchased from American Type Culture Collection (Rockville, MD, USA). Primary human epidermal keratinocytes (HEKs) from human infant foreskin were obtained from the Vanderbilt University Skin Disease Research Center. Primary human mammary epithelial cells (HMECs) from two females (#1012 and #1016) were isolated and provided by S Eltom (Meharry Medical College). Mouse keratinocyte (MK) cells were provided by B Weissman (University of North Carolina, Chapel Hill, NC, USA). EpH4 cells were provided by C Arteaga (Vanderbilt University). KC (mouse keratinocytes transformed with K-ras) cells were derived from BALB/MK cells by Kirsten murine sarcoma virus transformation, as described previously [58]. HaCaT cells were provided by P Boukamp (Deutsches Krebsforschungszentrum, Heidelberg, Germany). MCT cells were provided by E Neilson (Vanderbilt University). Panc-1 tumor cells were provided by L Matrisian (Vanderbilt University). Colo357 tumor cells were provided by M Korc (University of California, Irvine, CA, USA). SCC012 and SCC028 cells were provided by D Sidransky (Johns Hopkins University, Baltimore, MD, USA). Finally, UNC10 cells were provided by W Yarbrough (Vanderbilt University).
###end p 18
###begin p 19
###xml 212 218 <span type="species:ncbi:9913">bovine</span>
###xml 624 630 <span type="species:ncbi:9913">bovine</span>
A549, Colo357, DU145, EpH4, H1299, HaCaT, HBL100, MCT, Panc-1, and 4T1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM)/high-glucose medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS). BT549 cells were maintained in RPMI-1640 medium (HyClone) supplemented with 10% FBS and 10 mug/ml insulin. NMuMG cells were maintained in DMEM/high-glucose medium supplemented with 10% FBS and 10 mug/ml insulin. HMEC-1016 and HMEC-1012 were grown in DMEM:F12 medium (1:1) (GibCoBRL, Grand Island, NY, USA) supplemented with 1% FBS, 10 mug/ml ascorbic acid, 2 nmol/l beta-estradiol, 35 mug/ml bovine pituitary extract, 1 ng/ml cholera toxin, 12.5 ng/ml epidermal growth factor (EGF), 0.1 mmol/l ethanolamine, 0.1 mmol/l phospho-ethanolamine, 1 mug/ml hydrocortisone, 1 mug/ml insulin, 0.2 mmol/l L-glutamine, 10 nmol/l T3, 10 mug/ml transferrin, and 15 nmol/l sodium selenite.
###end p 19
###begin p 20
###xml 123 125 123 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 426 431 <span type="species:ncbi:9796">horse</span>
HEKs were maintained in EpiLife medium supplemented with human keratinocyte growth supplement (S-001-5) and 0.06 mol/l CaCl2 (Cascade Biologics, Portland, OR, USA). MCF-7 cells were maintained in minimal essential medium (MEM; GibCoBRL) supplemented with 10% FBS, 10 mug/ml insulin, 1% nonessential amino acids, and 22 mug/ml sodium pyruvate. MCF10A cells were cultured in (1:1) DMEM:F12 medium (Hyclone) supplemented with 5% horse serum, 100 ng/ml cholera toxin, 20 ng/ml EGF, 500 ng/ml hydrocortisone, and 10 mug/ml insulin. MDA-MB-231, -361, -435S, and -436 cells were maintained in McCoy's 5A medium (HyClone) supplemented with 10% FBS. MDA-MB-468 cells were grown in DMEM/high-glucose:McCoy's 5A medium (1:1) supplemented with 10% FBS. MK and KC cells were maintained in DMEM/high-glucose medium supplemented with 8% dialyzed FBS, 5 mug/ml calcium, and 4 ng/ml EGF. SCC012 and SCC028 cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 1% insulin-transferrin-selenium A, 1% L-glutamine, and 1% non-essential amino acids. UNC10 cells were grown in DMEM/ high-glucose medium supplemented with 10% FBS, 1% insulin-transferrin-selenium A, 1% L-glutamine, and 1% nonessential amino acids.
###end p 20
###begin p 21
###xml 53 54 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 121 122 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
All cell lines were maintained at 37degreesC in 5% CO2, except for the NMuMG, MK, and KC cells, which were grown in 7% CO2.
###end p 21
###begin title 22
Antibodies and other reagents
###end title 22
###begin p 23
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
###xml 219 225 <span type="species:ncbi:9986">rabbit</span>
###xml 329 332 <span type="species:ncbi:10116">rat</span>
###xml 395 401 <span type="species:ncbi:9986">rabbit</span>
###xml 413 419 <span type="species:ncbi:9986">rabbit</span>
###xml 518 524 <span type="species:ncbi:9986">rabbit</span>
###xml 615 621 <span type="species:ncbi:9986">Rabbit</span>
###xml 627 631 <span type="species:ncbi:9925">goat</span>
###xml 633 637 <span type="species:ncbi:9925">goat</span>
###xml 643 648 <span type="species:ncbi:10090">mouse</span>
###xml 654 658 <span type="species:ncbi:9925">goat</span>
###xml 664 667 <span type="species:ncbi:10116">rat</span>
TGF-beta1 was from R&D Systems (Minneapolis, MN, USA). Antibodies to Smad2/3 (mouse) and E-cadherin (mouse) were from BD Transduction Laboratories (San Diego, CA, USA); antibodies to phosphorylated (Ser 465/467) Smad2 (rabbit lot #21034 and #24432) were from Upstate Biotechnology (Lake Placid, NY, USA); and antibodies to ZO-1 (rat) were from Chemicon International (Temecula, CA, USA). Smad3 (rabbit) and ZO-1 (rabbit ZR-1) antibodies were obtained from Zymed Laboratories Inc. (San Francisco, CA, USA). Anti-actin (rabbit) antibodies and streptavidin-Cy3 conjugate were obtained from Sigma (St. Louis, MO, USA). Rabbit anti-goat, goat anti-mouse, and goat anti-rat biotinylated antibodies were obtained from Vector Laboratories Inc. (Burlingame, CA, USA).
###end p 23
###begin title 24
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
[3H]Thymidine incorporation assays
###end title 24
###begin p 25
###xml 129 130 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Subconfluent cells were treated with TGF-beta1 (5 ng/ml) for 46 hours in 12-well plates and pulsed for 2 hours with 4 muCi/well [3H]thymidine (Perkin Elmer Life Sciences, Boston, MA, USA). Cells were fixed with 1 ml 10% trichloroacetic acid for 30 min at 25degreesC, followed by two washes with 10% trichloroacetic acid. DNA was solubilized by incubation in 600 mul 0.2 N NaOH for 30 min, and radioactivity was counted using 200 mul solubilized DNA in 4 ml scintillation fluid.
###end p 25
###begin title 26
Flow cytometry analyses
###end title 26
###begin p 27
###xml 90 92 87 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
Subconfluent cells were treated with TGF-beta1 (5 ng/ml) for 48 hours and approximately 106 cells were incubated in propidium iodide solution (50 mug/ml propidium iodide (Sigma), 5 mug/ml RNase A, 0.1% Triton X-100, and 1 mug/ml sodium citrate) for 5-10 min. Stained cells were analyzed using a FACS Caliber (Becton-Dickinson, San Jose, CA, USA) and the data stored as listmode files. DNA cell cycle histograms were analyzed and modeled using ModFit and WinList software (Verity Software House, Topsham, ME, USA). Fifteen thousand events were analyzed for each sample.
###end p 27
###begin title 28
Cell lysis and immunoblot analyses
###end title 28
###begin p 29
###xml 202 203 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 205 206 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 851 857 <span type="species:ncbi:9986">rabbit</span>
###xml 932 938 <span type="species:ncbi:9986">rabbit</span>
After 2 hours or 48 hours of treatment with TGF-beta1 (5 ng/ml), cells were lysed in protein lysis buffer (50 mmol/l Tris pH 7.5, 100 mmol/l NaCl, 0.5% NP-40, 50 mug/ml PMSF, 4 mmol/l NaF, 0.1 mmol/l Na3VO4) supplemented with protease inhibitors, and protein concentrations in cell lysates were determined using the Bradford method. Protein extracts (100 mug/lane) were separated by 12% SDS-PAGE and transferred to polyvinylidene fluoride membranes (Immobilon-P; Millipore, Bedford, MA, USA). Membranes were blocked in 5% nonfat dry milk in Tris buffered saline with Tween-20 (TTBS; 150 mmol/l NaCl, 100 mmol/l Tris, pH 7.5, 0.1% Tween-20) for 2 hours at 25degreesC. Membranes to be incubated in phosphorylated Smad2 antibodies lot #24432 were not blocked in milk. Membranes were incubated with primary antibodies diluted in TTBS buffer plus 1% milk (rabbit Smad2 1:1000, phosphorylated Smad2 1:1000 lot #21034 or 1:200 lot #24432, rabbit Smad3 1:300, actin 1:500) for 1 hour or overnight at 4degreesC for phosphorylated Smad2 lot #24432, washed for 20 min in TTBS buffer, and incubated in secondary antibodies diluted in TTBS buffer plus 1% milk (1:10000) for 1 hour at 25degreesC. Membranes were washed two times in TTBS buffer (45 min/wash) and immunoreactive bands were visualized by enhanced chemiluminescence.
###end p 29
###begin title 30
Immunofluorescence microscopy
###end title 30
###begin p 31
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 266 269 <span type="species:ncbi:10116">rat</span>
###xml 385 391 <span type="species:ncbi:9986">rabbit</span>
###xml 726 730 <span type="species:ncbi:9925">goat</span>
###xml 741 747 <span type="species:ncbi:9986">rabbit</span>
###xml 785 791 <span type="species:ncbi:9986">rabbit</span>
###xml 802 805 <span type="species:ncbi:10116">rat</span>
###xml 890 893 <span type="species:ncbi:10116">rat</span>
###xml 907 913 <span type="species:ncbi:9986">rabbit</span>
Subconfluent cells, grown on 22 mm2 glass cover slips (VWR Scientific, Atlanta, GA, USA), were treated for 48 hours or 6 days with 5 ng/ml TGF-beta1. After treatment, cells were washed once with phosphate buffered saline (PBS) and fixed with 100% cold methanol (for rat ZO-1 and E-cadherin antibody use), 4% paraformaldehyde/PBS (for F-actin staining), or 1% paraformaldehyde/PBS (for rabbit ZO-1 antibody use) for 20 min at 25degreesC. Cells were washed four times with PBS, permeabilized by incubation with 0.2% Triton X-100 (in PBS) for 10 min at 25degreesC, and then washed two more times with PBS. For ZO-1 and E-cadherin staining, nonspecific binding sites were blocked by cellular incubation for 2 hours with 5% serum (goat serum for rabbit ZO-1 and E-cadherin antibody use and rabbit serum for rat ZO-1 antibody use) in PBS, incubated in primary antibodies diluted in 5% serum/PBS (rat ZO-1 1:1000, rabbit ZO-1 1:100, and E-cadherin 1:2500) for 1 hour at 25degreesC, followed by four washes with PBS. Cells were incubated in appropriate biotinylated secondary antibodies diluted in 5% serum/PBS (1:250) for 1 hour at 25degreesC, washed four times with PBS, and incubated in streptavidin-conjugated Cy3 diluted in 5% serum/PBS (1:1000) for 1 hour at 25degreesC. Cells were washed four times with PBS and nuclei were counter-stained by incubation with 0.1 mug/ml Hoechst (33258) for 15 min at 25degreesC. For F-actin staining, cells were incubated in Texas Red-X phalloidin (Molecular Probes Inc., Eugene, OR, USA) diluted in PBS (1:200) for 30 min, washed with PBS three times, and were counterstained with Hoechst as described above.
###end p 31
###begin p 32
After Hoechst staining, cells were washed three times with PBS and cover slips were mounted onto 25 x 75 mm microslides (Fisher Scientific, Pittsburgh, PA, USA) using AquaPolyMount (Polysciences, Warrington, PA, USA). Phase contrast images were captured using the Zeiss Epifluorescence inverted microscope and Zeiss AxioCam digital camera (Carl Zeiss, Jena, Germany). Fluorescent images were captured using the Zeiss Axiophot upright microscope (Carl Zeiss) and the Princeton Instruments cooled CCD digital camera (Princeton Scientific Instruments, Inc., Monmouth Junction, NJ, USA).
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Transforming growth factor-beta1 induced epithelial to mesenchymal transition in NMuMG and MCT cells
###end title 34
###begin p 35
###xml 53 61 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 205 206 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 402 403 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 805 816 796 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a,1e,1i,1m</xref>
###xml 841 852 832 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b,1f,1j,1n</xref>
###xml 869 880 860 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c,1g,1k,1o</xref>
###xml 955 966 946 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d,1h,1l,1p</xref>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 129 134 <span type="species:ncbi:10090">mouse</span>
###xml 272 277 <span type="species:ncbi:9606">human</span>
###xml 313 318 <span type="species:ncbi:9606">human</span>
To determine the frequency of TGF-beta1-mediated EMT in vitro, we performed a screen of 18 established cell lines from human and mouse epidermis, mammary gland, lung, pancreas, kidney, and prostate (Table 1). In addition to the established cell lines, primary cultures of human epidermal keratinocytes (HEKs) and human mammary gland epithelial cells (HMEC-1012 and HMEC-1016) were also screened (Table 1). In the present study, EMT was defined as acquisition of a spindle-shaped morphology, loss of ZO-1 and E-cadherin from cell-cell junctions, and formation of actin stress fibers after TGF-beta1 treatment. Using phase contrast and immunofluorescence microscopy, we determined that only two cell lines underwent EMT. After 48 hours of TGF-beta1 treatment, the NMuMG and MCT cells became elongated (Fig. 1a,1e,1i,1m), lost E-cadherin (Fig. 1b,1f,1j,1n) and ZO-1 (Fig. 1c,1g,1k,1o) staining at cell-cell junctions, and developed actin stress fibers (Fig. 1d,1h,1l,1p).
###end p 35
###begin p 36
###xml 224 235 221 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a,2e,2i,2m</xref>
###xml 342 353 339 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2d,2h,2l,2p</xref>
###xml 454 465 451 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b,2f,2j,2n</xref>
###xml 611 622 605 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c,2g,2k,2o</xref>
The primary cultures of breast epithelial cells (HMEC-1012 and HMEC-1016) acquired a spindle-shaped morphology, whereas the primary cultures of HEKs did not change cell morphology after 48 hours of TGF-beta1 treatment (Fig. 2a,2e,2i,2m; and data not shown). In addition, the HMECs and HEKs developed actin stress fibers after treatment (Fig. 2d,2h,2l,2p; and data not shown). However, the HMECs and HEKs did not lose junctional E-cadherin staining (Fig. 2b,2f,2j,2n; and data not shown) after TGF-beta1 treatment for 48 hours. These cells also had little or no ZO-1 localized to their cell-cell junctions (Fig. 2c,2g,2k,2o; and data not shown).
###end p 36
###begin p 37
###xml 76 81 76 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a,3e</xref>
###xml 136 147 136 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b,3f,3c,3g</xref>
###xml 276 281 273 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d,3h</xref>
###xml 353 358 350 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3i,3m</xref>
###xml 390 395 387 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3l,3p</xref>
###xml 456 467 453 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3j,3n,3k,3o</xref>
###xml 776 811 764 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b,4f,4r,4v,4c,4g,4s,4w,4d,4h,4t,4x</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human breast epithelial cell line MCF10A did not become elongated (Fig. 3a,3e) or lose junctional E-cadherin or ZO-1 staining (Fig. 3b,3f,3c,3g) in response to 48 hours of TGF-beta1 treatment. After treatment, these cells exhibited some actin stress fiber formation (Fig. 3d,3h). However, the MCF10A cells acquired a spindle-shaped morphology (Fig. 3i,3m) and actin stress fibers (Fig. 3l,3p), and lost much of the junctional E-cadherin and ZO-1 (Fig. 3j,3n,3k,3o) after TGF-beta1 treatment for 6 days. The HaCaT, UNC10, A549, Colo357, DU145, MK, KC, and 4T1 cells also exhibited an actin stress fiber response to TGF-beta1, without delocalization of E-cadherin or ZO-1 from the cell-cell junctions, similar to the MCF10A cells after 48 hours of TGF-beta1 treatment (Fig. 4b,4f,4r,4v,4c,4g,4s,4w,4d,4h,4t,4x; and data not shown).
###end p 37
###begin p 38
###xml 313 336 310 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4i,4j,4k,4l,4m,4n,4o,4p</xref>
###xml 588 589 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Other cell lines screened did not exhibit any changes in cell morphology or relocalization of E-cadherin, ZO-1, or actin after treatment with TGF-beta1. These cell lines included SCC012, SCC028, HBL100, BT549, MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-435S, MDA-MB-436, MDA-MB-468, H1299, Panc-1, and EpH4 cells (Fig. 4i,4j,4k,4l,4m,4n,4o,4p; and data not shown). A summary of the TGF-beta1-induced cellular response of the cell strains that exhibited acquisition of a spindle-shaped morphology, loss of junctional E-cadherin or ZO-1, or formation of actin stress fibers is presented in Table 2.
###end p 38
###begin title 39
Transforming growth factor-beta1-induced inhibition of S-phase
###end title 39
###begin p 40
###xml 291 293 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 466 467 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Previous studies analyzing TGF-beta1 induction of EMT have emphasized the stages in which TGF-beta1 acts as a promoter of carcinogenesis. It is proposed that cells first lose sensitivity to the growth inhibitory effects of TGF-beta1, before TGF-beta1 can promote EMT and cancer progression [59]. Therefore, we examined whether there was a correlation between TGF-beta1-mediated EMT and loss of sensitivity to the growth inhibitory effects of TGF-beta1 by examining [3H]thymidine incorporation and flow cytometry.
###end p 40
###begin p 41
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 345 346 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 357 358 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 432 433 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 635 636 629 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 647 648 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 729 730 723 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 824 825 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 836 837 827 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 908 909 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 920 921 911 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1034 1035 1025 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1079 1080 1067 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1091 1092 1079 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
In [3H]thymidine incorporation experiments, it was observed that 41% of the cell strains screened had a 0-25% reduction in [3H]thymidine incorporation (or 75% of the control) after 48 hours of TGF-beta1 treatment. These cells included SCC028, UNC10, HBL100, MDA-MB-361, MDA-MB-435S, MDA-MB-436, MDA-MB-468, H1299, Colo357, Panc-1, and 4T1 (Fig. 5 and Table 3). Similarly, 37% of the cell strains screened had a 25-75% reduction in [3H]thymidine incorporation (or 75-25% of the control) after 48 hours of TGF-beta1 treatment. These cells included HaCaT, SCC012, HMEC (1016), MCF10A, BT549, MCF7, MDA-MB-231, A549, DU145, and EpH4 (Fig. 5 and Table 3). Only 22% of the cell strains screened showed greater than a 75% reduction in [3H]thymidine incorporation (or 25% of the control) after 48 hours of TGF-beta1 treatment (Fig. 5 and Table 3). These cells included HEK, HMEC (1012), MK, KC, NMuMG, and MCT (Fig. 5 and Table 3). Of note, established cell lines constituted 95% of the cells that did not have greater than 75% reduction in [3H]thymidine after TGF-beta1 treatment (Fig. 5 and Table 3).
###end p 41
###begin p 42
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 241 242 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 243 244 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 245 246 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 247 248 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 249 250 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 338 339 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 464 465 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 470 471 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 634 635 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 736 747 727 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d,1h,1l,1p</xref>
###xml 754 765 745 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2d,2h,2l,2p</xref>
###xml 772 783 763 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d,3h,3I,3p</xref>
###xml 790 801 781 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d,4h,4t,4x</xref>
###xml 808 809 799 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
Most of the cell lines that did not have a greater than 75% reduction in [3H]thymidine incorporation after TGF-beta1 treatment, did not exhibit changes in morphology or changes in actin, E-cadherin, or ZO-1 localization in this screen (Figs 1,2,3,4,5; and data not shown). Only the UNC10, A549, and DU145 cell lines did not have reduced [3H]thymidine incorporation of greater than 75% and had increased actin stress fiber formation after TGF-beta1 treatment (Figs 4 and 5; and data not shown). However, there was no change in ZO-1 localization in these cells (data not shown). In comparison, all of the cell lines that had decreased [3H]thymidine incorporation had increased actin stress fiber formation after TGF-beta1 treatment (Fig. 1d,1h,1l,1p; Fig. 2d,2h,2l,2p; Fig. 3d,3h,3I,3p; Fig. 4d,4h,4t,4x; Fig. 5; and data not shown). These cells included the HaCaT, MCF10A, Colo357, MK, KC, NMuMG, 4T1, and MCT cells, and the primary cultures of HMEC-1012 and HEK cells.
###end p 42
###begin p 43
###xml 113 114 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 221 222 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 254 255 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 260 261 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 273 274 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 282 283 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
Flow cytometry was also performed on cells treated with TGF-beta1 for 48 hours to confirm the data generated by [3H]thymidine incorporation. The data generated by flow cytometry experiments were consistent with those of [3H]thymidine incorporation (Figs 5 and 6, and Table 3). Fig. 6 includes histograms that were representative of cell strains with 0-25% (MDA-MB-436), 25-75% (EpH4), and 75-100% (NMuMG) reduction in S-phase after 48 hours of TGF-beta1 treatment, when compared with the control cells.
###end p 43
###begin title 44
Transforming growth factor-beta1-mediated Smad2 phosphorylation did not correlate with S-phase reduction
###end title 44
###begin p 45
###xml 427 428 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 439 440 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 722 723 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 728 729 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 741 742 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 975 976 966 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
To determine the relationship of Smad2 phosphorylation with reduction in S-phase and EMT, after TGF-beta1 treatment, we analyzed phosphorylated Smad2 protein levels. Western analyses of protein extracts showed that, after 2 hours of treatment with TGF-beta1, phosphorylated Smad2 protein levels increased in all of the cell strains screened except for the MCF7, MDA-MB-361, and MDA-MB-435S cells when normalized to actin (Fig. 7 and Table 3). After treatment with TGF-beta1 for 48 hours, levels of phosphorylated Smad2 remained elevated in the cells with increased levels of phosphorylated Smad2 after 2 hours of treatment, except HMEC (1016), HBL100, MCF10A, MDA-MB-436, H1299, MK, and MCT when normalized to actin (Figs 7 and 8, and Table 3). Immunoblot analysis of the MCF7, MDA-MB-361, and MDA-MB-435S cells with the phosphorylated Smad2 antibody (lot #21034) resulted in a band (indicated by an asterisk) that migrated higher than the phosphorylated Smad2 protein (Fig. 7).
###end p 45
###begin p 46
###xml 115 116 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 212 213 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 218 219 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 231 232 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 264 265 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 454 455 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 457 458 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 463 464 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 476 477 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Cell strains that exhibited TGF-beta1-induced phosphorylation of Smad2 did not necessarily exhibit a reduction in [3H]thymidine uptake. These cell strains included SCC028, MDA-MB-436, MDA-MB-468, and H1299 (Figs 5 and 7, and Table 3). Although the MCF7 cells had [3H]thymidine uptake of 59% of the control after 48 hours of TGF-beta1 treatment, an increase in phosphorylation of Smad2 by Western analysis was not observed at 2 hours or at 48 hours (Figs 5, 7 and 8, and Table 3).
###end p 46
###begin title 47
Prolonged transforming growth factor-beta1 treatment led to decreased total Smad2 and Smad3 protein levels in many cell strains
###end title 47
###begin p 48
###xml 125 126 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 311 312 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 492 493 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
Total Smad2 and Smad3 protein levels decreased with TGF-beta1 treatment in 51% and 48% of the cell lines, respectively (Fig. 8). Total Smad2 levels decreased in HEK, HaCaT, SCC012, UNC10, BT549, MDA-MB-231, MDA-MB-361, MDA-MB-435S, H1299, Colo357, NMuMG, EpH4, 4T1, and MCT cells when normalized to actin (Fig. 8). Total Smad3 levels decreased in HEK, HMEC (1012 and 1016), HaCaT, SCC012, SCC028, UNC10, BT549, MDA-MB-231, MDA-MB-436, A549, EpH4, and 4T1 cells when normalized to actin (Fig. 8).
###end p 48
###begin p 49
###xml 236 237 233 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 382 383 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 388 389 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 401 402 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 491 492 485 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 637 638 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 643 644 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 656 657 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 711 712 702 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 827 828 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 833 834 821 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 846 847 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Decreased total Smad2 and total Smad3 protein levels did not correlate with an increased reduction in S-phase after TGF-beta1 treatment for 48 hours. For instance, the HMEC (1012), MK, and KC cells had a 87%, 81%, and 89% reduction in [3H]thymidine incorporation, respectively, whereas there was no decrease in total Smad2 protein levels after 48 hours of TGF-beta1 treatment (Figs 5 and 8, and Table 3). Similarly, the MK, KC, MCT, and NMuMG cells had 81%, 89%, 76%, and 92% reductions in [3H]thymidine incorporation, respectively, whereas there was no decrease in total Smad3 protein levels after 48 hours of TGF-beta1 treatment (Figs 5 and 8, and Table 3). In contrast, the HEK cells had a 98% reduction in [3H]thymidine incorporation and had no reduction of total Smad2 or Smad3 after 48 hours of TGF-beta1 treatment (Figs 5 and 8, and Table 3).
###end p 49
###begin p 50
###xml 167 168 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 173 174 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 186 187 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 377 378 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 511 512 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 523 524 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 760 761 748 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 766 767 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 779 780 767 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Also, decreased total Smad2 and Smad3 protein levels did not correlate with an increase in the levels of phosphory-lated Smad2 protein after TGF-beta1 treatment (Figs 7 and 8, and Table 3). An increase in phosphorylated Smad2 protein levels occurred in all cell strains screened after 2 hours of TGF-beta1 treatment except for the MCF7, MDA-MB-361, and MDA-MB-435S cells (Fig. 7), whereas only a subset of those had decreased total Smad2 and/or Smad3 protein levels after TGF-beta1 treatment for 48 hours (Fig. 8 and Table 3). Additionally, the MDA-MB-361 and the MDA-MB-435S cells did not have increased phosphorylated Smad2 levels or decreased total Smad3 levels, but they did exhibit decreased total Smad2 levels after 48 hours of TGF-beta1 treatment (Figs 7 and 8, and Table 3).
###end p 50
###begin p 51
###xml 217 218 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 357 358 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 521 522 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 523 524 508 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 525 526 510 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 544 545 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The decrease in total Smad2 and Smad3 protein levels, observed after TGF-beta1 treatment, did not associate with the ability of the cell line to undergo TGF-beta1-mediated EMT. NMuMG and MCT cells underwent EMT (Fig. 1) and they both exhibited decreased total Smad2 and no decrease in total Smad3 protein levels after TGF-beta1 treatment for 48 hours (Fig. 8). The other cell lines that had decreased total Smad2 and no decrease in total Smad3 levels after TGF-beta1 treatment did not undergo TGF-beta1-induced EMT (Figs 2,3,4 and 8, and Table 3; and data not shown).
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 182 184 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 263 269 <span type="species:ncbi:10090">murine</span>
###xml 285 290 <span type="species:ncbi:10090">mouse</span>
###xml 449 454 <span type="species:ncbi:9606">human</span>
###xml 485 490 <span type="species:ncbi:9606">human</span>
###xml 495 500 <span type="species:ncbi:10090">mouse</span>
TGF-beta1 is an inhibitor of epithelial cell growth in the early stages of carcinogenesis. However, it also promotes tumor cell invasion and metastasis through the induction of EMT [52]. Many studies on the mechanism of TGF-beta1-induced EMT are limited to a few murine cell lines and mouse models. Therefore, to identify alternative cell systems in which to study TGF-beta1-induced EMT, we performed a TGF-beta1 sensitivity screen using a panel of human primary cells and established human and mouse cell lines.
###end p 53
###begin p 54
###xml 170 181 164 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a,1e,1i,1m</xref>
###xml 188 193 182 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2i,2m</xref>
###xml 216 218 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 219 221 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 427 450 421 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a,1d,1e,1h,1i,1l,1m,1p</xref>
###xml 457 468 451 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2i,2l,2m,2p</xref>
###xml 634 657 625 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b,1f,1j,1n,1c,1g,1k,1o</xref>
###xml 908 910 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 911 913 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 914 916 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1048 1050 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1051 1053 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1290 1292 1275 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1293 1295 1278 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1296 1298 1281 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1299 1301 1284 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 1434 1436 1413 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1437 1439 1416 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 1554 1555 1530 1531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1708 1719 1681 1692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c,3d,3g,3h</xref>
The TGF-beta1-induced morphologic changes observed in the NMuMG, MCT, and HMEC cells 48 hours after TGF-beta1 treatment are consistent with changes seen during EMT (Fig. 1a,1e,1i,1m; Fig. 2i,2m; and data not shown) [53,54]. Changes in cell morphology, from a cobblestone-like appearance to more elongated shape, and actin stress fiber formation, were observed in the NMuMG and MCT cells, and in primary cultures of HMECs (Fig. 1a,1d,1e,1h,1i,1l,1m,1p; Fig. 2i,2l,2m,2p; and data not shown). However, only the NMuMG and MCT cells lost E-cadherin and ZO-1 staining at the cell-cell junctions after 48 hours of TGF-beta1 treatment (Fig. 1b,1f,1j,1n,1c,1g,1k,1o). E-cadherin is a protein found at adherens junctions that allows for cell-cell adherence, and ZO-1 is a tight junctional protein that forms a selective barrier between cells. Loss of these proteins at cell-cell junctions is used as a marker of EMT [54,60-63]. Cortical actin is a measure of cell integrity and loss thereof, or formation of actin stress fibers, is also used to define EMT [63,64]. Therefore, we concluded that only the NMuMG and MCT cells underwent TGF-beta1-mediated EMT, after 48 hours of treatment, in this screen. Results from previous studies also show that NMuMG and MCT cells undergo TGF-beta1-mediated EMT [60,61,63-65]. Other studies reported that TGF-beta1-mediated EMT occurs in HaCaT, Colo357, and Panc-1 cells 48 hours after TGF-beta1 treatment [66,67]; however, they did not undergo TGF-beta1-induced EMT according to the conditions used in the present study (Fig. 4). Other cell lines screened in the study formed actin stress fibers with TGF-beta1 treatment, but they did not lose ZO-1 from cell-cell junctions (Fig. 3c,3d,3g,3h; and data not shown). We did not examine E-cadherin localization in all of the cell strains because not all of the cell strains exhibited morphologic changes, with TGF-beta1 treatment, that were indicative of EMT.
###end p 54
###begin p 55
###xml 369 392 360 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3i,3j,3k,3l,3m,3n,3o,3p</xref>
###xml 543 545 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 546 548 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 549 551 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 552 554 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 885 887 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 888 890 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 193 198 <span type="species:ncbi:9606">human</span>
###xml 1028 1033 <span type="species:ncbi:9606">human</span>
Unlike the mouse NMuMG and MCT cells, none of the 14 human cell lines with an epithelial morphology screened underwent TGF-beta1-mediated EMT within 48 hours of TGF-beta1 treatment. The MCF10A human breast epithelial cell line took 6 days to undergo a morphologic change, lose junctional E-cadherin and ZO-1, and form actin stress fibers with TGF-beta1 treatment (Fig. 3i,3j,3k,3l,3m,3n,3o,3p). However, this extended treatment with TGF-beta1 to induce EMT is not consistent with previous reports that used times up to and including 48 hours [60,61,66,67]. It may be that the extended treatment with TGF-beta1 is necessary to activate secondary and tertiary signaling pathways that are not activated within 48 hours. The Panc-1, Colo357, and HaCaT cells were treated with TGF-beta1 for longer than 48 hours because they were shown to undergo TGF-beta1-induced EMT in previous reports [66,67]. However, these cell lines did not undergo EMT when treated with TGF-beta1 for 72 hours (data not shown). These data could suggest that human cells are more resistant to TGF-beta1-mediated EMT. Alternatively, the TGF-beta1 treatment times were not long enough to induce EMT, the small sample size used may not be representative, or the cells may not have the genetic alterations necessary for TGF-beta1 to induce EMT.
###end p 55
###begin p 56
###xml 311 313 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 314 316 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 464 466 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 608 610 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 661 663 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 697 699 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 708 710 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 751 753 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 791 793 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 794 796 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 797 799 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 211 216 <span type="species:ncbi:9606">human</span>
###xml 218 221 <span type="species:ncbi:10116">rat</span>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 326 331 <span type="species:ncbi:10090">mouse</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
Activation of non-Smad signaling pathways is also implicated in TGF-beta1-mediated EMT. Many studies have shown a requirement for activated Ras/Raf/mitogen-activited protein kinase for TGF-beta1-mediated EMT in human, rat, or mouse epidermal, pancreas, intestine, liver, prostate, and mammary epithelial cells [67-76]. In the mouse mammary gland epithelial cell line EpH4, TGF-beta1 induces EMT and tumor formation in mice only when cells express oncogenic H-Ras [73]. Furthermore, it has been shown that TGF-beta1 can activate Ras, and increased H-Ras levels are required for nuclear accumulation of Smad2 [70]. Additionally, signaling through integrin beta1 [68] and activation of EGF receptor [62], RhoA [61], p38 mitogen-activited protein kinase [77], and phosphatidylinositol 3-kinase [60,70,71] pathways are involved in or required for TGF-beta1-induced EMT.
###end p 56
###begin p 57
###xml 120 128 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 334 341 325 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 408 410 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 411 413 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 414 416 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 417 419 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 420 422 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 423 425 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 552 554 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 555 557 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 131 136 <span type="species:ncbi:9606">human</span>
###xml 145 150 <span type="species:ncbi:9606">Human</span>
###xml 244 249 <span type="species:ncbi:9606">human</span>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 394 399 <span type="species:ncbi:9606">human</span>
The lack of TGF-beta1-mediated EMT in the human cells does not necessarily refute a role for TGF-beta1 in promoting EMT in vivo in human tumors. Human epithelial tumors can undergo mesenchymal conversions, providing a potential role for EMT in human metastasis. It has been shown that excess TGF-beta1 can promote EMT in human tumors in vivo. Increased levels of TGF-beta1 are observed in many human tumors [35-40,42,51,78-80], are often localized to the advancing edges of primary tumors and metastases, and are associated with poor clinical outcome [39,41].
###end p 57
###begin p 58
###xml 133 141 130 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 258 259 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 260 261 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 757 765 745 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 766 768 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 141 146 <span type="species:ncbi:10090">mouse</span>
###xml 325 330 <span type="species:ncbi:10090">mouse</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
It is somewhat unexpected that TGF-beta1-induced EMT occurred in nontransformed cell lines, such as the NMuMG and MCT cells, because in vivo mouse studies show that TGF-beta1 promotes tumor cell invasion and metastasis in the later stages of carcinogenesis [5,6]. In one of these studies, targeted expression of TGF-beta1 to mouse suprabasal keratinocytes results in resistance to the formation of benign skin tumors, after long-term chemical carcinogenesis treatment. However, benign papillomas that develop become malignant at an accelerated rate and metastasis occur more rapidly than spontaneous tumors in control mice. Additionally, there are a high incidence of spindle cell carcinoma development in these mice, pointing to TGF-beta1-induction of EMT in vivo [38]. NMuMG and MCT cells may have the genetic alterations that allow for TGF-beta1-mediated EMT to occur.
###end p 58
###begin p 59
###xml 267 269 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 492 494 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 495 497 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 498 500 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 501 503 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 808 809 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 811 812 784 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 818 819 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 909 911 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 1117 1119 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 279 285 <span type="species:ncbi:10090">murine</span>
###xml 307 313 <span type="species:ncbi:10090">murine</span>
Many studies on TGF-beta1-mediated EMT have emphasized that TGF-beta1 promotes carcinogenesis in stages. It is proposed that cells first lose sensitivity to the growth inhibitory effects of TGF-beta1, and subsequently TGF-beta1 can promote tumor progression and EMT [59]. MMH-D3 murine hepatocytes and EpH4 murine mammary gland epithelial cells undergo TGF-beta1-mediated EMT only when rendered insensitive to TGF-beta1-induced cell cycle arrest or apoptosis, by infection with active H-Ras [59,70,73,81]. However, the present study does not support this model because it shows that resistance to the growth inhibitory effects of TGF-beta1 is not a prerequisite for TGF-beta1-mediated EMT. The NMuMG and MCT cells exhibited a decrease in S-phase and underwent EMT after 48 hours of TGF-beta1 treatment (Figs 1, 5, and 6). Consistent with the present study were experiments performed by Nicolas and coworkers [72] that showed that increased Smad3 in MDCK cells restored growth inhibitory responses to TGF-beta1 but did not revert cells from a mesenchymal to an epithelial phenotype. Additionally, Chang and coworkers [49] observed that increased TGF-beta1 expression in sarcoma cells increased cell tumori-genicity while inhibiting cell proliferation.
###end p 59
###begin p 60
###xml 91 92 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 433 434 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 649 650 649 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
The trends observed with the analysis of the flow cytometry data were consistent with the [3H]thymidine incorporation data (Figs 5 and 6 and Table 3). However, the values for the percentage of the control cells in S-phase were not identical between [3H]thymidine incorporation and flow cytometry for each cell strain. This discrepancy can be accounted for by the fact that the data were generated using two different methodologies. [3H]thymidine incorporation examines DNA synthesis during the last 2 hours of the 48-hour period, whereas flow cytometry examines DNA synthesis at the 48-hour time-point. Although the numeric data generated from the [3H]thymidine incorporation and flow cytometry experiments were not the same, the trends of TGF-beta1-induced decreases in DNA synthesis were consistent.
###end p 60
###begin p 61
###xml 493 494 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 495 496 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 497 498 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 509 510 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 917 918 896 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 919 920 898 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 921 922 900 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 934 935 913 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
All but three of the cell strains screened had an increase in phosphorylated Smad2 protein levels after 2 hours of TGF-beta1 treatment, but not all of the cell lines that had increased phosphorylation of Smad2 had reduced S-phase after 48 hours of TGF-beta1 treatment. The SCC028, MDA-MB-436, MDA-MB-468, and H1299 cells had an increase in phosphorylated Smad2 levels after 2 hours of TGF-beta1 treatment, but they exhibited decreases in S-phase of only 5%, 1%, 4%, and 4%, respectively (Figs 5,6,7 and Table 3). The lack of S-phase decrease upon 48 hours of TGF-beta1 treatment may point to inactivation of or mutations in downstream proteins that could abolish TGF-beta1-mediated growth inhibition in these cells. The MCF7 cells did not exhibit an increase in phosphorylated Smad2 protein levels after 2 hours of TGF-beta1 treatment, but there was a 41% decrease in S-phase on 48 hours of TGF-beta1 treatment (Figs 5,6,7, and Table 3). This decrease in S-phase is not as great a decrease as was exhibited by some of the other cell strains when treated with TGF-beta1 for 48 hours. The decrease could be explained by very low levels of phosphorylated Smad2 increase on TGF-beta1 treatment that was not detected by immunoblot analysis. Alternatively, it is possible that the TGF-beta1 signal was propagated by phosphorylation of Smad3.
###end p 61
###begin p 62
###xml 380 382 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 406 408 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 332 337 <span type="species:ncbi:9606">human</span>
Smad2 is not solely responsible for the propagation of TGF-beta1 signals. Similar to Smad2, on TGF-beta1 binding to the TbetaRII, Smad3 is phosphorylated by the TbetaRI, forms a complex with Smad4, translocates to nucleus, and regulates the activation of TGF-beta1 target genes. However, mutations or deletions in Smad3 are rare in human cancers. Reports by Graham and coworkers [82] and Xu and coworkers [83] suggest that loss of Smad3 may largely be responsible for the nonresponsiveness of some cells to TGF-beta1. The proliferation, migration, and invasion of normal extravillous trophoblast cells are under the control of TGF-beta1. However, premalignant and malignant trophoblast cells, that have lost the Smad3 protein but retain functional Smad2, are resistant to the antiproliferative and anti-invasive effect of TGF-beta1. It is therefore possible that the attenuation of inhibition of S-phase or the induction of EMT by TGF-beta1 in the present study may be a result of mutation or loss of Smad3, even though the cells have increased phosphorylation of Smad2 on TGF-beta1 treatment.
###end p 62
###begin p 63
###xml 236 237 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 238 239 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 240 241 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 242 243 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 378 380 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 589 591 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 592 594 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 658 660 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 757 759 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 760 762 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 882 884 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 885 887 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 629 634 <span type="species:ncbi:9606">human</span>
###xml 796 801 <span type="species:ncbi:9606">human</span>
Interestingly, decreased total Smad2 and Smad3 protein levels were observed after TGF-beta1 treatment regardless of changes in the levels of phosphorylated Smad2 protein or of whether cell proliferation was inhibited by TGF-beta1 (Figs 5,6,7,8). Similar to our findings, decreased total Smad2 protein levels were reported in COS-1 monkey kidney cells after TGF-beta1 treatment [84]. In that report, the proteasome inhibitors MG-132 or lactacystin blocked Smad2 from TGF-beta1-induced degradation. In addition, Smad3 decreases have been reported during TGF-beta1-induced EMT in MDCK cells [72,85] and after TGF-beta1 treatment of human lung epithelial cells [86]. In these studies, MDCK cells become refractory to the growth inhibitory effects of TGF-beta1 [72,85]. TGF-beta1 treatment of primary human fibroblasts and HaCaT cells also leads to decreased total Smad3 protein levels [87,88].
###end p 63
###begin p 64
###xml 234 236 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 237 239 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 343 345 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 346 348 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 427 429 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 430 432 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
###xml 493 498 487 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Fbw1a</sup>
###xml 562 564 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 844 846 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B93">93</xref>
###xml 949 951 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B94">94</xref>
###xml 952 954 937 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B96">96</xref>
A negative feedback loop could explain the decreases in total Smad2 and Smad3 protein levels after 48 hours of TGF-beta1 treatment. The E3 ubiquitin ligase Smurf has been shown to interact with Smads and promote their ubiquitination [89,90]. In this model, phosphorylated, nuclear Smad2 is ubiquitinated by Smurf2 and degraded by proteasomes [89,90]. Smad7 also interacts with Smurf2 and induces TGF-beta receptor degradation [91,92]. Phosphorylated Smad3 is also ubiquitinated by the ROC1-SCFFbw1aE3 ligase complex, and subsequently degraded in the proteasome [88]. In order to prevent continuous Smad signaling in the absence of TGF-beta1 stimulation, Smad2 and Smad3 are negatively regulated by a number of proteins. Smad6 and Smad7 inhibit Smad2 and Smad3 activation by competing with Smad2 and Smad3 for binding to the TGF-beta receptors [93]. Smad6 and Smad7 are induced by activation of TGF-beta1 signaling and form a negative feedback loop [94-96]. However, the mechanism of decrease in total Smad2 and/or Smad3 in different cell strains on prolonged TGF-beta1 treatment remains unclear.
###end p 64
###begin title 65
Conclusion
###end title 65
###begin p 66
###xml 48 57 45 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 506 515 491 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 589 597 571 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
TGF-beta1 induction of EMT is a rare occurrence in vitro and is not limited to transformed cell lines. In fact, TGF-beta1-mediated EMT was only observed in nontumorigenic cells in the present study. Furthermore, there does not appear to be a correlation between loss of TGF-beta-mediated growth inhibition and EMT. The inability of TGF-beta1 to induce EMT was not due to a total loss of TGF-beta1 signaling, as was evidenced by induction of Smad2 phosphorylation. In conclusion, our data indicate that the in vitro models used to study TGF-beta1 induction of EMT may not be as relevant to in vivo cancer progression as was previously assumed in the field.
###end p 66
###begin title 67
Competing interests
###end title 67
###begin p 68
None declared.
###end p 68
###begin title 69
Abbreviations
###end title 69
###begin p 70
###xml 130 136 <span type="species:ncbi:9913">bovine</span>
###xml 150 155 <span type="species:ncbi:9606">human</span>
###xml 188 193 <span type="species:ncbi:9606">human</span>
###xml 224 229 <span type="species:ncbi:10090">mouse</span>
###xml 305 310 <span type="species:ncbi:10090">mouse</span>
DMEM = Dulbecco's modified Eagle's medium; EGF = epidermal growth factor; EMT = epithelial to mesenchymal transition; FBS = fetal bovine serum; HEK = human epidermal keratinocytes; HMEC = human mammary epithelial cell; KC = mouse keratinocytes transformed with K-ras; MEM = minimal essential medium; MK = mouse keratinocyte; PBS = phosphate buffered saline; Smad = Sma/Mothers Against Decapentaplegic; TbetaRI = TGF-beta type I receptor; TbetaRII = TGF-beta type II receptor; TGF = transforming growth factor; TTBS = Tris buffered saline with Tween-20; ZO = zonula occludens.
###end p 70
###begin title 71
Acknowledgements
###end title 71
###begin p 72
We thank the Vanderbilt University Toxicology Center tissue culture core facility (supported by NIH grant ES00267) and the Vanderbilt University Medical Center Cell Imaging Core Resource (supported by NIH grants CA68485 and DK20593). We would also like to thank Dr Brian Law, Dr Neil Bhowmick, Dr Matthew Westfall, Jamie Hearnes, and Kristy Schavolt for critical reading of the manuscript. The present study was also supported by NIH training grant T32CA09592 to KAB and R01 CA85492 and R01 CA102162 to HLM.
###end p 72
###begin article-title 73
Transforming growth factor beta signal transduction
###end article-title 73
###begin article-title 74
Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity
###end article-title 74
###begin article-title 75
Mechanisms of TGF-beta-mediated apoptosis
###end article-title 75
###begin article-title 76
Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation
###end article-title 76
###begin article-title 77
TGF-beta signaling in tumor suppression and cancer progression
###end article-title 77
###begin article-title 78
TGF-beta signaling in cancer: a double-edged sword
###end article-title 78
###begin article-title 79
TGF-beta signaling: positive and negative effects on tumorigenesis
###end article-title 79
###begin article-title 80
The TGF-beta-Smad network: introducing bioinformatic tools
###end article-title 80
###begin article-title 81
How cells read TGF-beta signals
###end article-title 81
###begin article-title 82
Role of transforming growth factor-beta signaling in cancer
###end article-title 82
###begin article-title 83
Regulation of cell proliferation by Smad proteins
###end article-title 83
###begin article-title 84
TGF-beta signalling from cell membrane to nucleus through SMAD proteins
###end article-title 84
###begin article-title 85
Transcriptional control by the TGF-beta/Smad signaling system
###end article-title 85
###begin article-title 86
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation
###end article-title 86
###begin article-title 87
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development
###end article-title 87
###begin article-title 88
###xml 78 83 <span type="species:ncbi:9606">human</span>
Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells
###end article-title 88
###begin article-title 89
Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases
###end article-title 89
###begin article-title 90
A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression
###end article-title 90
###begin article-title 91
###xml 72 77 <span type="species:ncbi:9606">human</span>
Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines
###end article-title 91
###begin article-title 92
###xml 91 96 <span type="species:ncbi:9606">human</span>
Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta
###end article-title 92
###begin article-title 93
###xml 159 164 <span type="species:ncbi:9606">human</span>
Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer
###end article-title 93
###begin article-title 94
A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
###end article-title 94
###begin article-title 95
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
###end article-title 95
###begin article-title 96
Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers
###end article-title 96
###begin article-title 97
###xml 73 78 <span type="species:ncbi:9606">human</span>
TGF-beta receptors and DNA repair genes, coupled targets in a pathway of human colon carcinogenesis
###end article-title 97
###begin article-title 98
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas
###end article-title 98
###begin article-title 99
###xml 107 112 <span type="species:ncbi:9606">human</span>
Analysis of specific gene mutations in the transforming growth factor-beta signal trans-duction pathway in human ovarian cancer
###end article-title 99
###begin article-title 100
Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas
###end article-title 100
###begin article-title 101
###xml 89 94 <span type="species:ncbi:9606">human</span>
Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer
###end article-title 101
###begin article-title 102
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer
###end article-title 102
###begin article-title 103
###xml 110 115 <span type="species:ncbi:9606">human</span>
Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers
###end article-title 103
###begin article-title 104
###xml 43 48 <span type="species:ncbi:9606">human</span>
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
###end article-title 104
###begin article-title 105
Frequent loss of SMAD4/DPC4 protein in colorectal cancers
###end article-title 105
###begin article-title 106
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
###end article-title 106
###begin article-title 107
TGF-beta 1 and skin carcinogenesis: antiproliferative effect in vitro and TGF-beta 1 mRNA expression during epidermal hyperproliferation and multistage tumorigenesis
###end article-title 107
###begin article-title 108
Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma
###end article-title 108
###begin article-title 109
###xml 57 62 <span type="species:ncbi:9606">human</span>
Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma
###end article-title 109
###begin article-title 110
Growth factor expression in normal, benign, and malignant breast tissue
###end article-title 110
###begin article-title 111
###xml 107 112 <span type="species:ncbi:9606">human</span>
Immuno-histochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer
###end article-title 111
###begin article-title 112
Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast
###end article-title 112
###begin article-title 113
###xml 151 156 <span type="species:ncbi:9606">human</span>
Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma
###end article-title 113
###begin article-title 114
Expression of transforming growth factor-beta 1 in prostate cancer
###end article-title 114
###begin article-title 115
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases
###end article-title 115
###begin article-title 116
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype
###end article-title 116
###begin article-title 117
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion
###end article-title 117
###begin article-title 118
Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1
###end article-title 118
###begin article-title 119
Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects
###end article-title 119
###begin article-title 120
Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro
###end article-title 120
###begin article-title 121
Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells
###end article-title 121
###begin article-title 122
Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma
###end article-title 122
###begin article-title 123
Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential
###end article-title 123
###begin article-title 124
Genetic events and the role of TGF beta in epithelial tumour progression
###end article-title 124
###begin article-title 125
Epithelial-mesenchymal transitions in tumour progression
###end article-title 125
###begin article-title 126
Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition
###end article-title 126
###begin article-title 127
Epithelial-mesenchymal transitions in development and tumor progression
###end article-title 127
###begin article-title 128
Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells
###end article-title 128
###begin article-title 129
Role of cell-matrix contacts in cell migration and epithelial-mesenchymal transformation
###end article-title 129
###begin article-title 130
###xml 34 62 <span type="species:ncbi:11808">Kirsten murine sarcoma virus</span>
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
Isolation and characterization of Kirsten murine sarcoma virus-transformed mouse ker-atinocytes resistant to transforming growth factor beta
###end article-title 130
###begin article-title 131
Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells
###end article-title 131
###begin article-title 132
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration
###end article-title 132
###begin article-title 133
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism
###end article-title 133
###begin article-title 134
###xml 183 186 <span type="species:ncbi:9823">pig</span>
Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes
###end article-title 134
###begin article-title 135
TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors
###end article-title 135
###begin article-title 136
TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells
###end article-title 136
###begin article-title 137
Early role of Fsp1 in epithelial-mesenchymal transformation
###end article-title 137
###begin article-title 138
Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta
###end article-title 138
###begin article-title 139
Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdif-ferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation
###end article-title 139
###begin article-title 140
Integrin b1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity
###end article-title 140
###begin article-title 141
Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells
###end article-title 141
###begin article-title 142
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness
###end article-title 142
###begin article-title 143
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways
###end article-title 143
###begin article-title 144
Epithelial mesenchymal transition in MDCK cells is accompanied by downregulation of Smad3 expression leading to resistance to TGFbeta-induced growth arrest
###end article-title 144
###begin article-title 145
TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells
###end article-title 145
###begin article-title 146
TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis
###end article-title 146
###begin article-title 147
Metastasis is driven by sequential elevation of H-ras and Smad2 levels
###end article-title 147
###begin article-title 148
###xml 164 169 <span type="species:ncbi:9606">human</span>
Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer
###end article-title 148
###begin article-title 149
p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration
###end article-title 149
###begin article-title 150
###xml 76 79 <span type="species:ncbi:10116">rat</span>
Autocrine production of TGF-alpha and TGF-beta during tumour progression of rat oral keratinocytes
###end article-title 150
###begin article-title 151
Transforming growth factor beta 1 expression in benign and malignant prostatic tumors
###end article-title 151
###begin article-title 152
###xml 119 124 <span type="species:ncbi:9606">human</span>
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors
###end article-title 152
###begin article-title 153
###xml 192 195 <span type="species:ncbi:10116">rat</span>
Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-beta 1) and alters the number and type of TGF-beta 1 receptors in rat intestinal epithelial cell clones
###end article-title 153
###begin article-title 154
Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta
###end article-title 154
###begin article-title 155
###xml 82 87 <span type="species:ncbi:9606">human</span>
Expression of TGF-beta signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells
###end article-title 155
###begin article-title 156
Ubiquitin-dependent degradation of TGF-beta-activated smad2
###end article-title 156
###begin article-title 157
Epithelial to mesenchymal transition in Madin-Darby canine kidney cells is accompanied by down-regulation of Smad3 expression, leading to resistance to transforming growth factor-beta-induced growth arrest
###end article-title 157
###begin article-title 158
###xml 99 104 <span type="species:ncbi:9606">human</span>
Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells
###end article-title 158
###begin article-title 159
###xml 0 34 <span type="species:ncbi:11908">Human T-cell leukemia virus type I</span>
Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-binding protein/p300
###end article-title 159
###begin article-title 160
Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins
###end article-title 160
###begin article-title 161
Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling
###end article-title 161
###begin article-title 162
Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase
###end article-title 162
###begin article-title 163
Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation
###end article-title 163
###begin article-title 164
Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation
###end article-title 164
###begin article-title 165
The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling
###end article-title 165
###begin article-title 166
Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling
###end article-title 166
###begin article-title 167
Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members
###end article-title 167
###begin article-title 168
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells
###end article-title 168
###begin title 169
Figures and Tables
###end title 169
###begin p 170
###xml 141 147 138 144 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a,e) </bold>
###xml 157 163 154 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i,m) </bold>
###xml 288 298 279 289 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b,f,j,n) </bold>
###xml 310 320 301 311 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c,g,k,o) </bold>
###xml 349 359 340 350 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d,h,l,p) </bold>
NMuMG and MCT cells underwent transforming growth factor (TGF)-beta1-mediated epithelial to mesenchymal transition. Phase contrast images of (a,e) NMuMG and (i,m) MCT cells with (TGF-beta1) and without (control) TGF-beta1 treatment (5 ng/ml) for 48 hours. Immunofluorescence detection of (b,f,j,n) E-cadherin, (c,g,k,o) zonula occludens (ZO)-1, and (d,h,l,p) F-actin in NMuMG and MCT cells treated with 5 ng/ml TGF-beta1 (TGF-beta1) or without TGF-beta1 (control) for 48 hours. TGF-beta1 induced cell elongation, loss of cortical actin and junctional E-cadherin and ZO-1 staining, and formation of actin stress fibers in NMuMG and MCT cells. Micrographs are representative of at least three independent experiments.
###end p 170
###begin p 171
###xml 197 203 194 200 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a,e) </bold>
###xml 211 217 208 214 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i,m) </bold>
###xml 344 354 335 345 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b,f,j,n) </bold>
###xml 366 376 357 367 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c,g,k,o) </bold>
###xml 405 415 396 406 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d,h,l,p) </bold>
###xml 91 96 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
Transforming growth factor (TGF)-beta1 induced spindle-shaped morphology in nontransformed human mammary epithelial cells (HMECs) and human epidermal keratinocytes (HEKs). Phase contrast images of (a,e) HEK and (i,m) HMEC cells with (TGF-beta1) and without (control) TGF-beta1 treatment (5 ng/ml) for 48 hours. Immuno-fluorescence detection of (b,f,j,n) E-cadherin, (c,g,k,o) zonula occludens (ZO)-1, and (d,h,l,p) F-actin in HEK and HMEC cells treated with 5 ng/ml TGF-beta1 (TGF-beta1) or without TGF-beta1 (control) for 48 hours. TGF-beta1 induced cell elongation and formation of actin stress fibers in the HEK and HMEC cells. However, junctional E-cadherin staining remained intact after TGF-beta1 treatment. ZO-1 was not detected in the HEK cells and little was observed in the HMEC cells with or without TGF-beta1 treatment. Micrographs are representative of at least three independent experiments.
###end p 171
###begin p 172
###xml 261 267 252 258 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a,e) </bold>
###xml 279 285 270 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i,m) </bold>
###xml 325 335 316 326 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b,f,j,n) </bold>
###xml 347 357 338 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c,g,k,o) </bold>
###xml 367 377 358 368 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d,h,l,p) </bold>
Elongation and loss of junctional E-cadherin and zonula occludens (ZO)-1 after prolonged transforming growth factor (TGF)-beta1 treatment in MCF10A cells. Phase contrast images of MCF10A cells treated with (TGF-beta1) or without (control) 5 ng/ml TGF-beta1 for (a,e) 48 hours or (i,m) 6 days. Immunofluorescence detection of (b,f,j,n) E-cadherin, (c,g,k,o) ZO-1, and (d,h,l,p) F-actin in MCF10A cells treated with TGF-beta1) or without (control) 5 ng/ml TGF-beta1 for 48 hours or 6 days. TGF-beta1 treatment induced cell elongation and formation of actin stress fibers in the MCF10A cells after 6 days of TGF-beta1 treatment but not after 48 hours. MCF10A cells also lost some junctional E-cadherin and ZO-1 after 6 days of treatment with TGF-beta1. Micrographs are representative of at least three independent experiments.
###end p 172
###begin p 173
###xml 152 158 149 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a,e) </bold>
###xml 167 173 164 170 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i,m) </bold>
###xml 185 191 182 188 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(q,u) </bold>
###xml 313 327 304 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b,f,j,n,r,v) </bold>
###xml 339 353 330 344 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c,g,k,o,s,w) </bold>
###xml 382 396 373 387 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d,h,l,p,t,x) </bold>
Transforming growth factor (TGF)-beta1 did not induce epithelial to mesenchymal transition in Colo357, Panc-1, or HaCaT Cells. Phase contrast images of (a,e) Colo357, (i,m) Panc-1, and (q,u) HaCaT cells treated with (TGF-beta1) or without (control) 5 ng/ml TGF-beta1 for 48 hours. Immunofluorescence detection of (b,f,j,n,r,v) E-cadherin, (c,g,k,o,s,w) zonula occludens (ZO)-1, and (d,h,l,p,t,x) F-actin in Colo357, Panc-1, and HaCaT cells treated with (TGF-beta1) or without (control) 5 ng/ml TGF-beta1 for 48 hours. TGF-beta1 treatment induced cell enlargement and formation of actin stress fibers in the Colo357 cells. However, junctional E-cadherin and ZO-1 remained intact after TGF-beta1 treatment. Changes in cell morphology, E-cadherin, ZO-1, or actin localization were not observed in the Panc-1 and HaCaT cells. Micrographs are representative of two experiments.
###end p 173
###begin p 174
###xml 252 253 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 532 533 524 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 599 600 591 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 706 707 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 92 97 <span type="species:ncbi:9606">Human</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 126 131 <span type="species:ncbi:10090">mouse</span>
Many cancer cell lines were not growth inhibited by transforming growth factor (TGF)-beta1. Human primary cells and human and mouse established cell lines were treated with TGF-beta1 (5 ng/ml) for 48 hours. The cells were then pulsed for 2 hours with [3H]thymidine, and incorporated radioactivity was quantified. Results are presented as the average percentage of control (untreated cells) incorporation (+/- standard error) from three independent experiments with 6-12 replicates per experiment. The average percentage of control [3H]thymidine incorporation was calculated by dividing the average [3H]thymidine incorporation of TGF-beta1-treated cells (from three independent experiments) by the average [3H]thymidine incorporation of nontreated cells (from three independent experiments) and then multiplying by 100%. Epid, epidermoid; Kid, kidney; Panc, pancreas; Pros, prostate.
###end p 174
###begin p 175
###xml 738 740 726 728 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 752 753 740 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 890 891 878 879 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 104 109 <span type="species:ncbi:9606">Human</span>
###xml 128 133 <span type="species:ncbi:9606">human</span>
###xml 138 143 <span type="species:ncbi:10090">mouse</span>
Transforming growth factor (TGF)-beta1 induced a robust decrease in S-phase in non-cancer cell strains. Human primary cells and human and mouse established cell lines were treated with (TGF-beta1) or without (control) 5 ng/ml TGF-beta1 for 48 hours. The cells were then harvested and incubated with propidium iodide, and DNA content was determined using a FACS Caliber (Becton-Dickinson). Data were modeled and analyzed using ModFit and WinList software (Verity Software House). Fifteen thousand events were analyzed for each sample. Representative histograms are presented illustrating cells that had a robust decrease in S-phase (NMuMG), modest decrease in S-phase (EpH4), and no decrease in S-phase (MDA-MB-436) as a result of TGF-beta1 treatment. G0/G1 and G2 phases are indicated by black shading and S phase is indicated by gray shading on the histograms. The percentage of cells in G0/G1 and in S phases of the cell cycle are indicated. Three independent experiments were performed with three replicates per experiment.
###end p 175
###begin p 176
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:10090">mouse</span>
###xml 181 186 <span type="species:ncbi:9606">human</span>
Transforming growth factor (TGF)-beta1 induced Smad2 phosphorylation in many cancer and noncancer cell strains. Twenty-four human and mouse established cell lines and three primary human cell cultures were treated with TGF-beta1 (5 ng/ml) for 2 hours. Extracts from control (-) and treated (+) cells were prepared and subjected to immunoblot analyses using antibodies for phosphorylated Smad2 (Ser 465/467), total Smad2, total Smad3, or actin. A signal of higher molecular weight, that is not phosphorylated Smad2, is indicated by an asterisk.
###end p 176
###begin p 177
###xml 47 49 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 140 145 <span type="species:ncbi:9606">human</span>
###xml 150 155 <span type="species:ncbi:10090">mouse</span>
###xml 197 202 <span type="species:ncbi:9606">human</span>
Prolonged transforming growth factor (TGF)-beta1 treatment induced a decrease in total Smad2 and/or Smad3 in many cell strains. Twenty-four human and mouse established cell lines and three primary human cell cultures were treated with TGF-beta1 (5 ng/ml) for 48 hours. Extracts from control (-) and treated (+) cells were prepared and subjected to immunoblot analyses using antibodies for phosphorylated Smad2 (Ser 465/467), total Smad2, total Smad3, or actin.
###end p 177
###begin p 178
Tissue origin, description, and morphology of cell strains used
###end p 178
###begin p 179
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
aHuman mammary epithelial cells (HMECs) from patients #1012 and #1016. HEK, primary human epidermal keratinocytes; MK, mouse keratinocytes.
###end p 179
###begin p 180
###xml 71 79 68 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Summary of transforming growth factor-beta1-induced cellular responses in vitro
###end p 180
###begin p 181
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 77 78 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 119 120 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 202 203 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 370 371 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 244 249 <span type="species:ncbi:9606">human</span>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
aTreatment with 5 ng/ml transforming growth factor (TGF)-beta1 for 48 hours. bDetermined by phase contrast microscopy. cDetermined by E-cadherin, zonula occludens (ZO)-1, or F-actin immunofluorescence. dHuman epidermal keratinocytes (HEKs) and human mammary epithelial cells (HMECs) exhibited little to no junctional ZO-1 staining in the absence of TGF-beta1 treatment. eHMECs from patients #1012 and #1016. Cellular responses to TGF-beta1 designated by + (strong), +/- (weak), or - (negative).
###end p 181
###begin p 182
###xml 90 98 87 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Summary of transforming growth factor-beta1-mediated Smad signaling and effect on S-phase in vitro
###end p 182
###begin p 183
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 77 78 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 256 257 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 350 352 338 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 353 354 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 368 369 356 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 529 530 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 693 694 681 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 787 788 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g</sup>
###xml 1025 1030 <span type="species:ncbi:9606">human</span>
###xml 1061 1066 <span type="species:ncbi:9606">human</span>
###xml 1096 1101 <span type="species:ncbi:10090">mouse</span>
###xml 1144 1149 <span type="species:ncbi:10090">mouse</span>
aTreatment with 5 ng/ml transforming growth factor (TGF)-beta1 for 48 hours. bSimilar results obtained after 2 hours TGF-beta1 treatment except those designated by an asterisk (detected increased phosphorylated Smad2 after 2 hours of TGF-beta1 treatment). cNo decrease in total Smad2 or total Smad3 was detected after 2 hours of TGF-beta1 treatment. d [3H]Thymidine ([3H]T) experiments performed at least three times with 6-12 replicates. Results are presented as the average percent of control of three independent experiments. eFlow cytometry experiments performed at least three times in triplicate. Results are presented as the average percent of control of three independent experiments. fAn increase in total Smad3 was observed in Colo357 cells 48 hours after TGF-beta1 treatment. gAccurate flow cytometry analysis could not be performed on BT549 cells because multiple populations of cells were present in the culture. Cellular responses to TGF-beta1 designated as + (positive response) or - (negative response). HEK, human epidermal keratinocyte; HMEC, human mammary epithelial cell; KC, mouse keratinocytes transformed with K-ras; MK, mouse keratinocyte.
###end p 183

